01-01-1970 12:00 AM | Source: ICICI Direct
Buy Hester Biosciences Ltd For Target Rs.2835 - ICICI Direct
News By Tags | #872 #2894 #3961 #642 #1302

Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel

https://t.me/InvestmentGuruIndiacom

Download Telegram App before Joining the Channel

Poultry drives Q2 as exports face logistic challenges

About the stock: Hester is one of India’s leading animal healthcare companies & the second largest poultry vaccine manufacturer in the country. It has a strategic presence in 30+ countries with key markets being India, Nepal and Tanzania.

* It operates through four broad verticals: poultry vaccines, poultry health products, animal vaccines and animal health products

* Revenue segment wise: poultry healthcare:73%, animal healthcare: 19%, others:8%; by geography: domestic:81%, exports:10%, others:9%

 

Q2FY22 Results: Hester reported strong Q2FY22 results.

* Sales were up 17.3% YoY to | 62.7 crore

* EBITDA in Q2FY22 was at | 17.6 crore, up 11% YoY with margins at 28%

* Consequent adjusted PAT was at | 10.6 crore (up 59% YoY)

 

What should investors do? Hester’s share price has grown by ~3x over the past five years (from ~| 778 in July 2016 to ~| 2368 levels in July 2021).

* We change our view from HOLD to BUY on account of positive impact of expected improvement in exports

Target Price and Valuation: We value Hester at | 2835 (base business at | 2756 i.e. 40x P/E on FY23E EPS + NPV of | 79 Covaxin DS opportunity)

 

Key triggers for future price performance:

* Opportunities in animal vaccines such as classical swine fever, lumpy skin disease (only player) and sheep pox (only player) in the domestic space

* The management intends to move away from preventive healthcare to curative healthcare as a long term strategy

* Increased focus on health products & widening of portfolio with differentiated herbal line of products looks promising for growth prospects

* Traction from vaccines manufactured in Tanzania facility, Hester Africa

 

Alternate Stock Idea: Apart from Hester, in our healthcare coverage we like Indoco.

* Indoco manufactures and markets branded formulations and APIs for the domestic and export markets.

* BUY with target price of | 575

 

 

To Read Complete Report & Disclaimer Click Here

 

https://secure.icicidirect.com/Content/StaticData/Disclaimer.html

 

Above views are of the author and not of the website kindly read disclaimer